Clinical trials: Recurrent Tumor
Ovarian Cancer
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-resistant recurrent ovarian cancer patients receiving gemcitabine and carboplatin.
- Trial name
- NCT01033292
- Testing
- BSI-201
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Sanofi
Relapsed and Refractory Multiple Myeloma
Efficacy Study of CYT997 in Multiple Myeloma
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.
- Trial name
- NCT00664378
- Testing
- CYT997
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Non-Small Cell Lung Cancer
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell…
- Trial name
- CheckMate-1533 (NCT06946797)
- Testing
- Nivolumab, Ipilimumab, Carboplatin
- Where
- 38 sites in United States, Brazil and 7 more
- Volunteers
- 76 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Pericarditis
Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis.
- Trial name
- NCT05107934
- Testing
- RPH-104
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- R-Pharm Overseas, Inc.
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Recurrent Glioblastoma
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing…
- Trial name
- NCT04440358
- Testing
- Exablate BBBD, Carboplatin
- Where
- 3 sites in Canada, Italy and 1 more
- Volunteers
- 13 people
- Sponsor
- InSightec
Urothelial Carcinoma
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
This was a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in…
- Trial name
- NCT03502785
- Testing
- INO-5401, INO-9012, Atezolizumab
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Inovio Pharmaceuticals
Multiple Myeloma
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT05164250
- Testing
- REGN5458
- Sponsor
- Regeneron Pharmaceuticals
Esophageal Stricture
INGEST I Pilot Study
INGEST I Pilot study is a feasibility study for evaluating the safety and efficacy of DCBs.
- Trial name
- INGEST (NCT03885310)
- Testing
- GIE Drug Coated Balloon
- Where
- Paraguay
- Volunteers
- 9 people
- Sponsor
- GIE Medical
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Head and Neck Carcinoma
Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.
This phase I study of an accelerator-based boron neutron capture therapy (BNCT) in the treatment of locally recurrent head and neck carcinoma, is sponsored by HUS, Haartmaninkatu 4, Helsinki, Finland and Neutron Therapeutics…
- Trial name
- BNCT (NCT07058116)
- Testing
- L-Boronophenylalanine intravenous administration
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- Neutron Therapeutics, LLC
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or…
- Conditions
- Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
- Trial name
- NCT03328078
- Testing
- Emavusertib, Ibrutinib
- Where
- 45 sites in United States, Czechia and 5 more
- Volunteers
- 152 people
- Sponsor
- Curis, Inc.
Squamous Cell Carcinoma of Head and Neck
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck.
- Trial name
- MONARCH (NCT00824343)
- Testing
- P276-00
- Where
- 9 sites in India
- Volunteers
- 86 people
- Sponsor
- Piramal Enterprises Limited
Cancer of the Breast
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
The study hypothesis is that the addition of Mycograb to docetaxel will improve outcome in advanced carcinoma of the breast.
- Trial name
- NCT00217815
- Testing
- Mycograb, Docetaxel
- Where
- 3 sites in Poland, Serbia
- Volunteers
- 20 people
- Sponsor
- NeuTec Pharma
Neoplasms, Triple Negative Breast Cancer
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer.
- Conditions
- Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- TOPACIO (NCT02657889)
- Testing
- niraparib, pembrolizumab
- Where
- 30 sites in United States
- Volunteers
- 122 people
- Sponsor
- Tesaro, Inc.
Relapsed/Refractory Non-Hodgkin's Lymphoma
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.
- Trial name
- NCT02095574
- Testing
- [14C]ABT-199 (GDC-0199)
- Sponsor
- AbbVie
Recurrent/Metastatic Head and Neck Cancer
Treatment of Recurrent/Metastatic Head and Neck Cancer
This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous)…
- Trial name
- NCT07601204
- Testing
- TQB2922 Subcutaneous Injection
- Where
- 10 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.